Moderna CMO Jacqueline Miller Steps Down as Company Seeks to Expand Beyond COVID Vaccines
核心洞察
Moderna's Chief Medical Officer Jacqueline Miller, who led development of the company's COVID-19 (搜索) vaccine Spikevax, will step down effective March 2, 2025.
Miller's departure comes at a pivotal moment as Moderna seeks to address declining COVID product demand and expand its mRNA platform into a broader therapeutic franchise.
The company has appointed David Berman, former head of R&D at Immunocore (搜索), as Chief Development Officer to replace Miller starting March 2.
Moderna announced Friday that Chief Medical Officer Jacqueline Miller will step down effective March 2, marking a significant leadership transition as the vaccine maker works to diversify beyond COVID-19 (搜索) products and establish its mRNA platform as a broader therapeutic franchise.
Miller, who joined Moderna in 2020 as therapeutic area head for infectious diseases, played a pivotal role in developing the company's mRNA-based COVID-19 (搜索) vaccine Spikevax. Her departure comes at a critical juncture for Moderna as the company seeks to address the revenue gap created by waning demand for COVID products.
Leadership Transition and Replacement
The company has named David Berman as Chief Development Officer, effective March 2. Berman brings extensive pharmaceutical experience, having previously served as head of research and development at Immunocore (搜索). His background also includes senior roles at major pharmaceutical companies AstraZeneca and Bristol-Myers Squibb (搜索).
Miller will remain with Moderna as a consultant to facilitate the leadership transition, the company stated.
Miller's Track Record in Vaccine Development
Throughout her career, Miller has supported seven novel vaccine approvals for patients across age groups from infants to older adults, according to Moderna's website. Her contributions at Moderna include not only the development of Spikevax but also the company's respiratory syncytial virus (搜索) vaccine mRESVIA.
Market Response
Moderna shares declined over 2% in premarket trading following the announcement, reflecting investor attention to the leadership change during this pivotal period for the company.
The timing of Miller's departure underscores the challenges facing Moderna as it works to transform from a COVID-focused vaccine company into a diversified mRNA therapeutics platform capable of generating sustained revenue across multiple therapeutic areas.